98%
921
2 minutes
20
Aim: To assess the direct effect of intensive glycaemic control on periodontal tissues in patients with diabetes mellitus.
Materials And Methods: Twenty-nine patients with type 2 diabetes were enrolled and hospitalized to receive a 2-week intensive glycaemic control regimen. We observed and analysed the systemic and oral disease indicators before and after treatment and clarified the indicators related to periodontal inflammation.
Results: A significant reduction in glycaemic and periodontal parameters, including glycated albumin levels and periodontal inflamed surface area (PISA), was observed after treatment. The changes in PISA per tooth, indicative of periodontal healing, exhibited a bimodal distribution; the patients were divided into two groups on this basis. Correlations were observed between the changes in PISA per tooth and fasting plasma glucose, acetoacetic acid, and beta-hydroxybutyrate levels in the PISA-improved group. Significantly lower levels of C-peptide, coefficient of variation of R-R interval, and ankle-brachial pressure index were observed before treatment in the PISA non-improved group.
Conclusions: Glycaemic control treatment can effectively improve periodontitis in patients with type 2 diabetes, even in the absence of specific periodontal treatments. However, the periodontal responsiveness to glycaemic control treatment depends on the systemic condition of the patient.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/dom.15835 | DOI Listing |
Eye (Lond)
September 2025
Department of Anesthesiology, Chi Mei Medical Center, Liouying, Tainan city, Taiwan.
Background: Diabetic retinopathy (DR) is the leading cause of preventable blindness. Although hyperglycaemia is the primary driver, other modifiable risk factors may contribute to DR development. This study investigated the association between haemoglobin levels and DR risk in adults with type 2 diabetes.
View Article and Find Full Text PDFBiochem Pharmacol
September 2025
Guizhou Medical University, Guiyang 550004 Guizhou, PR China; Department of Cardiovascular Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004 Guizhou, PR China; The Key Laboratory of Myocardial Remodeling Research, The Affiliated Hospital of Guizhou Medical University, G
Atherosclerosis (AS), a chronic inflammatory disease and a leading cause of cardiovascular morbidity and mortality. Macrophage-mediated lipid uptake and inflammation are central to plaque formation. TREM2, an immunoreceptor expressed in macrophages, has been reported to regulate lipid metabolism and inflammation, yet its role in atherosclerosis remains controversial.
View Article and Find Full Text PDFPhytomedicine
August 2025
Center for Clinical Reseach, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China. Electronic address:
Background: The management of kidney diseases urgently needs additional therapeutic options. Encouraging evidence suggests the efficacy of Huangkui capsules (HKCs), a plant-derived traditional medicine, in treating various subtypes of nephropathy. However, current evidence is fragmented between clinical outcomes and mechanistic insights.
View Article and Find Full Text PDFPhytomedicine
August 2025
School of Chinese Materia Medica, Beijing University of Chinese Medicine, 102488, China. Electronic address:
Background: Diabetic nephropathy (DN), a serious diabetic complication, currently has limited treatment options. Yulan Jiangtang capsules (YL) are a clinically approved traditional Chinese medicine formula for glycemic control and diabetes-related complications. Nevertheless, the underlying mechanisms of their therapeutic effects remain incompletely elucidated.
View Article and Find Full Text PDFJ Endocrinol Invest
September 2025
Department of Medicine-DIMED, University of Padova, Padova, Italy.
Background: Cushing's syndrome (CS) is associated with increased metabolic and cardiovascular (CV) risk factors and morbidities. Evidence-based guidelines for the management of these issues in active or remitted CS are not available, so best practice is derived from guidelines developed for the general population. We aimed to evaluate the awareness and practice variation for CV comorbidities of CS across Reference Centres (RCs) of the European Reference Network on Rare Endocrine Conditions (Endo-ERN).
View Article and Find Full Text PDF